Cord-blood-derived mesenchymal stromal cells downmodulate CD4+ T-cell activation by inducing il-10-producing th1 cells

Stem Cells and Development

Volumn 22, Issue 7, 2013, Pages 1063-1075

  Selleri, Silvia ^a,b   Dieng, Mame Massar ^a   Nicoletti, Simon ^a,c   Louis, Isabelle ^a   Beausejour, Christian ^a,b   Le Deist, Françoise ^a,b   Haddad, Elie ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 13; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7; JANUS KINASE 2; OX40 LIGAND; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 6; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CORD BLOOD DERIVED MESENCHYMAL STROMAL CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; UMBILICAL CORD BLOOD; UPREGULATION;

ANTIBODIES, BLOCKING; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; DOWN-REGULATION; FETAL BLOOD; HUMANS; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; RECEPTORS, INTERFERON; RECEPTORS, INTERLEUKIN-10; TH1 CELLS;

EID: 84875927209     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0315     Document Type: Article

References (50)

1. Bernardo ME, D Pagliara and F Locatelli. (2012). Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant 47:164-171.
2. Baron F, C Lechanteur, E Willems, F Bruck, E Baudoux, L Seidel, JF Vanbellinghen, K Hafraoui, M Lejeune, et al. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLAmismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16:838-847.
3. Kebriaei P, L Isola, E Bahceci, K Holland, S Rowley, J McGuirk, M Devetten, J Jansen, R Herzig, et al. (2009). Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15:804-811.
4. Ringden O, M Uzunel, I Rasmusson, M Remberger, B Sundberg, H Lonnies, HU Marschall, A Dlugosz, A Szakos, et al. (2006). Mesenchymal stem cells for treatment of therapy- resistant graft-versus-host disease. Transplantation 81:1390-1397.
5. Weng JY, X Du, SX Geng, YW Peng, Z Wang, ZS Lu, SJ Wu, CW Luo, R Guo, et al. (2010). Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 45:1732-1740.
6. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
7. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
8. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
9. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722-3729.
10. Le Blanc K, L Tammik, B Sundberg, SE Haynesworth and O Ringden. (2003). Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11-20.
11. English K and BP Mahon. (2011). Allogeneic mesenchymal stem cells: agents of immune modulation. J Cell Biochem 112:1963-1968.
12. Di Ianni M, B Del Papa, M De Ioanni, L Moretti, E Bonifacio, D Cecchini, P Sportoletti, F Falzetti and A Tabilio. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36:309-318.
13. Selmani Z, A Naji, I Zidi, B Favier, E Gaiffe, L Obert, C Borg, P Saas, P Tiberghien, et al. (2008). Human leukocyte antigen- G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3 + regulatory T cells. Stem Cells 26:212-222.
14. Salem HK and C Thiemermann. (2010). Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28:585-596.
15. Gregoire-Gauthier JL, S Selleri, FO Fontaine, MM Dieng, N Patey, GV Despars, CM Beaus Jour and L Haddad. (2012). Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graftversus- host disease in a xenogenic mouse model. Stem Cells Dev. 21:1616-1626
16. Cope A, G Le Friec, J Cardone and C Kemper. (2011). The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. Trends Immunol 32:278-286.
17. Mazza G, CA Sabatos-Peyton, RE Protheroe, A Herman, JD Campbell and DC Wraith. (2010). Isolation and characterization of human interleukin-10-secreting T cells from peripheral blood. Hum Immunol 71:225-234.
18. Haringer B, L Lozza, B Steckel and J Geginat. (2009). Identification and characterization of IL-10/IFN-gammaproducing effector-like T cells with regulatory function in human blood. J Exp Med 206:1009-1017.
19. English K, JM Ryan, L Tobin, MJ Murphy, FP Barry and BP Mahon. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3 + regulatory T cells. Clin Exp Immunol 156:149-160.
20. Prevosto C, M Zancolli, P Canevali, MR Zocchi and A Poggi. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92:881-888.
21. Mougiakakos D, R Jitschin, CC Johansson, R Okita, R Kiessling and K Le Blanc. (2011). The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117:4826-4835.
22. Meiler F, J Zumkehr, S Klunker, B Ruckert, CA Akdis and M Akdis. (2008). In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 205:2887- 2898.
23. Saraiva M, JR Christensen, M Veldhoen, TL Murphy, KM Murphy and A O'Garra. (2009). Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31:209-219.
24. Saraiva M and A O'Garra. (2010). The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170-181.
25. Selleri S, S Deola, Z Pos, P Jin, A Worschech, SL Slezak, C Rumio, MC Panelli, D Maric, et al. (2008). GM-CSF/IL-3/IL- 5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8 + T cells. J Transl Med 6:17.
26. Garcia-Olmo D, M Garcia-Arranz, D Herreros, I Pascual, C Peiro and JA Rodriguez-Montes. (2005). A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416-1423.
27. Dryden GW. (2009). Overview of stem cell therapy for Crohn's disease. Expert Opin Biol Ther 9:841-847.
28. Dahlke MH, M Hoogduijn, E Eggenhofer, FC Popp, P Renner, P Slowik, A Rosenauer, P Piso, EK Geissler, et al. (2009). Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 88:614-619.
29. Karussis D, C Karageorgiou, A Vaknin-Dembinsky, B Gowda-Kurkalli, JM Gomori, I Kassis, JW Bulte, P Petrou, T Ben-Hur, O Abramsky and S Slavin. (2010). Safety and immunological effects of mesenchymal stem cell transplanta- tion in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67:1187-1194.
30. Davatchi F, BS Abdollahi, M Mohyeddin, F Shahram and B Nikbin. (2011). Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 14:211-215.
31. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
32. Prasanna SJ, D Gopalakrishnan, SR Shankar and AB Vasandan. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5:e9016.
33. Groh ME, B Maitra, E Szekely and ON Koc. (2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 33: 928-934.
34. Bernabei P, A Allione, L Rigamonti, M Bosticardo, G Losana, I Borghi, G Forni and F Novelli. (2001). Regulation of interferon- gamma receptor (INF-gammaR) chains: a peculiar way to rule the life and death of human lymphocytes. Eur Cytokine Netw 12:6-14.
35. Refaeli Y, L Van Parijs, SI Alexander and AK Abbas. (2002). Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 196:999-1005.
36. Najar M, R Rouas, G Raicevic, HI Boufker, P Lewalle, N Meuleman, D Bron, M Toungouz, P Martiat and L Lagneaux. (2009). Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11:570-583.
37. Stumhofer JS, JS Silver, A Laurence, PM Porrett, TH Harris, LA Turka, M Ernst, CJ Saris, JJ O'Shea and CA Hunter. (2007). Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8:1363-1371.
38. Gandhi R, MF Farez, Y Wang, D Kozoriz, FJ Quintana and HL Weiner. (2010). Cutting edge: human latency-associated peptide + T cells: a novel regulatory T cell subset. J Immunol 184:4620-4624.
39. Han Y, Q Guo, M Zhang, Z Chen and X Cao. (2009). CD69 + CD4+ CD25 - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 182:111-120.
40. Soleymaninejadian E, K Pramanik and E Samadian. (2012). Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 67:1-8.
41. Giuliani M, M Fleury, A Vernochet, F Ketroussi, D Clay, B Azzarone, JJ Lataillade and A Durrbach. (2011). Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on Tlymphocyte proliferation. PLoS One 6:e19988.
42. Gieseke F, J Bohringer, R Bussolari, M Dominici, R Handgretinger and I Muller. (2010). Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116:3770-3779.
43. Ryan JM, F Barry, JM Murphy and BP Mahon. (2007). Interferon- gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
44. Francois M, R Romieu-Mourez, M Li and J Galipeau. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20:187-195.
45. Beyth S, Z Borovsky, D Mevorach, M Liebergall, Z Gazit, H Aslan, E Galun and J Rachmilewitz. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105:2214-2219.
46. Levitsky J, J Miller, J Leventhal, X Huang, C Flaa, E Wang, A Tambur, RK Burt, L Gallon and JM Mathew. (2009). The human ''Treg MLR'': immune monitoring for FOXP3 + T regulatory cell generation. Transplantation 88:1303-1311.
47. Daniel V, M Sadeghi, H Wang and G Opelz. (2012). CD4( + )CD25( + )Foxp3( + )IFNgamma( + ) Treg are immunosuppressive in vitro and increase with intensity of the alloresponse in pretransplant MLC. Transpl Immunol. 27:114-121.
48. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
49. Djouad F, LM Charbonnier, C Bouffi, P Louis-Plence, C Bony, F Apparailly, C Cantos, C Jorgensen and D Noel. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25:2025-2032.
50. Spaggiari GM, H Abdelrazik, F Becchetti and L Moretta. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576-6583.